Alcide Barberis
22Patents
5h-index
12Co-inventors
62Inventor score
Filing activity: Dec 18, 2000 → Oct 30, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9173935B2 | Phospholipid drug analogs | Emerging Cross-Sectional Technologies | 20 | Active |
| US8067547B2 | Stable and soluble antibodies inhibiting TNFα | Chemistry; Metallurgy | 15 | Active |
| US7258986B2 | Intrabodies with defined framework that is stable in a reducing environment and applications thereof | Chemistry; Metallurgy | 13 | Expired |
| US8853362B2 | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same | Chemistry; Metallurgy | 12 | Expired |
| US7902340B2 | Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK | Chemistry; Metallurgy | 6 | Active |
| US9540407B2 | Phospholipid drug analogs | Emerging Cross-Sectional Technologies | 3 | Active |
| US7258985B2 | Intrabodies with defined framework that is stable in a reducing environment and applications thereof | Chemistry; Metallurgy | 3 | Expired |
| US8945563B2 | Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK | Chemistry; Metallurgy | 2 | Active |
| US9683034B2 | Stable and soluble antibodies inhibiting TNFα | Chemistry; Metallurgy | 2 | Active |
| US9173936B2 | Phospholipid drug analogs | Emerging Cross-Sectional Technologies | 2 | Active |
| US9180183B2 | Phospholipid drug analogs | Emerging Cross-Sectional Technologies | 2 | Active |
| US9050319B2 | Phospholipid drug analogs | Human Necessities | 2 | Active |
| US6821728B1 | Screening system | Chemistry; Metallurgy | 1 | Expired |
| US10125186B2 | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same | Chemistry; Metallurgy | 0 | Active |
| US8691228B2 | Stable and soluble antibodies inhibiting TNFα | Chemistry; Metallurgy | 0 | Active |
| US8936785B2 | scFv antibodies which pass epithelial and/or endothelial layers | Chemistry; Metallurgy | 0 | Active |
| US10570190B2 | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same | Chemistry; Metallurgy | 0 | Active |
| US9518108B2 | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same | Chemistry; Metallurgy | 0 | Active |
| US9512411B2 | Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK | Chemistry; Metallurgy | 0 | Active |
| US8389693B2 | Stable and soluble antibodies inhibiting TNFα | Chemistry; Metallurgy | 0 | Active |
| US7566528B2 | Method for the identification and/or validation of receptor tyrosine kinase inhibitors | Physics | 0 | Expired |
| US9315572B2 | Stable and soluble antibodies inhibiting TNF alpha | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.